Treatment of IgG4-Related Disease With Revlimid and Rituximab

IgG4-related Disease Clinical Trial

— TIGR2  

Official title:

Treatment of IgG4-Related Disease With Revlimid and Rituximab: The TIGR2 Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02705638
• Other study ID #: 15-003700
• Status: Completed
• Phase: Phase 1
• Start date: April 2016
• Est. completion date: April 2019

Study information

• Verified date: July 2019
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Among persons with Immunoglobulin G subclass 4 Related Disease (IgG4)-related disease who have persistent or recurrent disease despite standard therapies, does combination therapy with rituximab and revlimid cause a sustained disease remission?

Description:

Immunoglobulin G subclass 4 Related Disease (IgG4-RD) is a recently recognized systemic fibroinflammatory condition. Various manifestations of IgG4-RD were previously recognized in individual organ systems, but these entities (including autoimmune pancreatitis, orbital pseudotumor, Reidel's thyroiditis, retroperitoneal fibrosis, idiopathic sialadenitis and dacryoadenitis, etc) are now recognized as manifestations of a common disease process that can affect any organ system. IgG4-RD is characterized by distinctive histologic findings of tissue infiltration by IgG4-positive plasma cells together with storiform fibrosis and obliterative phlebitis. Both clinical and pathologic consensus diagnostic criteria have been defined. Serum IgG4 concentration is a biomarker for IgG4-RD and is elevated in 70% to 90% of patients with active disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: April 2019
• Est. primary completion date: April 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

1. Diagnosis of active IgG4-RD based on standard pathologic or clinical criteria (see below) and requiring medical treatment

2. Patient is:

1. in relapse after prior steroid and/or rituximab (RTX) treatment or while tapering steroid treatment, OR

2. has disease that is refractory to steroids, OR

3. has contraindications to steroid therapy (including diabetes, mood disorder, obesity)

3. Absolute neutrophil count >1500 and platelet count >/= 100,000

4. Calculated creatinine clearance (or estimated GFR) greater than or equal to 60ml/min

5. In patients without hepatobiliary involvement by IgG4-RD, total bilirubin less than or equal to 1.5 x upper limit of normal (ULN), aspartate aminotransferase (AST) (SGOT) and alanine aminotransferase (ALT) (SGPT) less than or equal to 3 x ULN

6. Not pregnant or nursing

7. All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS™) program, and be willing and able to comply with the requirements of the REMS™ program

8. Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS™ program

9. Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid (ASA) may use warfarin or low molecular weight heparin)

10. Agrees to use acceptable methods of birth control during and for 12 months after completion of study drug therapy (applies to all men, and women of child bearing potential)

11. Females must follow pregnancy testing requirements as outlined in the Revlimid REMS™ program

Exclusion criteria:

1. Predominant changes of fibrosis (as opposed to active cellular inflammation) within the organs affected by IgG4-RD, such that the likelihood of a disease response to treatment is low

2. Presence of active infection that would interfere with therapy on this study, including positive serum hepatitis B surface antigen, HIV or active hepatitis C virus (HCV) infection, untreated syphilis or tuberculosis, clinical history of multiple herpes virus reactivations

3. Known immunodeficiency state

4. New York Heart Association Classification III or IV heart disease

5. Active malignancy requiring therapy

6. Receipt of a live vaccine within 4 weeks prior to initiating study drug therapy.

7. Allergies: History of severe allergic reactions to human or chimeric monoclonal antibodies, murine protein, or lenalidomide

8. Substance abuse: Drug or alcohol abuse that could interfere with participation in the trial according to the protocol

9. Known anti-human anti-chimeric antibody formation

10. Treatment with infliximab, adalimumab, or etanercept within the past 12 months.

11. Currently taking azathioprine, 6-mercaptopurine, methotrexate, mycophenolate mofetil, or other conventional immunomodulators. Patients receiving these drugs must discontinue them prior to enrollment

12. Other investigational medication within the previous one month

Related Conditions & MeSH terms

• Autoimmune Pancreatitis
• Cholangitis
• Cholangitis, Sclerosing
• IgG4-related Disease
• IgG4-related Sclerosing Cholangitis
• Immunoglobulin G Subclass 4 Related Disease
• Pancreatitis
• Retroperitoneal Fibrosis

Intervention

Drug:
• Rituximab
All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15.
• Lenalidomide
All subjects will receive Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.

Locations

Country	Name	City	State
United States	Mayo Clinic in Rochester	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Mayo Clinic	Celgene Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of subjects in remission for Immunoglobulin G subclass 4 Related Disease at 24 months		24 months